Serum autoantibody-based biomarkers for prognosis in early-stage lung cancer patients with surgical resection
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.Serum autoantibodies show promise as biomarkers for predicting lung cancer recurrence after surgery. Higher levels correlate with longer progression-free survival, suggesting a role in anti-tumor immunity.
Area Of Science
- Oncology
- Immunology
- Biomarker Discovery
Background
- Lung cancer presents a significant global health challenge with high mortality rates.
- Surgical intervention is increasingly common for early-stage lung cancer.
- Effective prognostic indicators for post-surgical recurrence risk are currently lacking.
Purpose Of The Study
- To investigate serum autoantibodies as potential biomarkers for predicting lung cancer recurrence post-surgery.
- To explore the functional roles of serum autoantibodies in anti-tumor immunity.
Main Methods
- Quantification of serum autoantibody levels in lung cancer patients and controls.
- In vitro assays including antibody-dependent cellular cytotoxicity (ADCC), antibody-dependent cellular phagocytosis (ADCP), and complement-dependent cytotoxicity (CDC).
Main Results
- Serum autoantibody-positive patients exhibited longer postoperative progression periods.
- Elevated serum autoantibody levels were observed in lung cancer patients compared to those with benign lung diseases.
- In vitro studies confirmed serum autoantibodies mediate immune responses and enhance anti-tumor effects.
Conclusions
- Serum autoantibodies represent promising biomarkers for assessing prognosis in lung cancer patients following surgery.
- Identification of these biomarkers is crucial for mitigating cancer recurrence risks.
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.